Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PIII files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received Nasdaq notice for failing to meet minimum stockholders' equity requirement and warns delisting remains possible if compliance lapses again by next quarterly report.
P3 Health regains Nasdaq compliance via $252M debt-for-equity swap, warns delisting risk remains
Filed May 15, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
high
Company converted $252M of debt owed to largest shareholder into non-voting preferred stock, eliminating debt but significantly diluting existing shareholders while avoiding immediate delisting.
Item 3.01 verify on EDGAR → -
high
Sold $30M of new preferred stock paying 19.5% annual dividends plus warrants to same affiliate, with up to $70M total authorized—expensive financing signaling financial stress.
Item 3.01 verify on EDGAR → -
high
Nasdaq warned company may face delisting again if stockholders' equity falls below $2.5M minimum by next quarterly report, making compliance fragile and temporary.
Item 3.01 verify on EDGAR → -
medium
Company met May 20, 2026 Nasdaq deadline with just weeks to spare after receiving extension in January following initial non-compliance notice.
Item 3.01 verify on EDGAR → -
medium
Filed pro forma balance sheet showing financial position as of March 31, 2026 reflecting the debt restructuring and new equity issuance.
Exhibit 99.1 view on EDGAR →
Summary
P3 Health Partners narrowly avoided Nasdaq delisting by completing an emergency financial restructuring with its largest shareholder, Chicago Pacific Founders. The company converted $252 million of debt into non-voting preferred stock and raised $30 million through expensive new preferred shares paying 19.5% annual dividends.
While this maneuver restored the minimum $2.5 million stockholders' equity required by Nasdaq, it came at significant cost: massive dilution to existing common shareholders and ongoing cash drain from high dividend obligations. The company's warning that it could face delisting again if equity falls below the threshold by its next quarterly report suggests the fix may be temporary.
The 19.5% dividend rate on new preferred stock—far above market rates—signals that P3 Health had limited financing options and reflects the high risk lenders see in the business. Existing shareholders now own a smaller piece of a heavily leveraged company dependent on its largest investor for survival. Retail investors should watch the next 10-Q filing closely to see whether stockholders' equity remains above Nasdaq's minimum and whether the company can generate enough cash to cover the expensive preferred dividends without further dilutive financing.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
P3 Health Partners disclosed a notice related to delisting or failure to satisfy continued listing standards.
Added in current filing · verify on EDGAR →
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
The company filed an 8-K under Item 3.01, which is triggered when a company receives notice from its exchange that it has failed to meet continued listing standards or faces potential delisting. This could relate to stock price, market capitalization, financial metrics, or other exchange requirements. The filing does not provide additional detail beyond the item heading.
Event · Item 8.01 — Other Events
Company regained Nasdaq compliance via $252M debt-for-equity exchange and $30M preferred stock sale to largest shareholder.
Added in current filing · verify on EDGAR →
As a result of completing the Debt Exchange and the initial issuances of Units, the Company believes that it has regained compliance with the Listing Rule.
Company regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement after previously failing to meet it. This was achieved through a debt-for-equity exchange and new preferred stock issuance. Nasdaq will continue monitoring compliance, and failure at the next periodic report could trigger delisting.
Added in current filing · verify on EDGAR →
Nasdaq provided the Company until January 5, 2026 to submit to Nasdaq a plan to regain compliance. The Company submitted the plan to regain compliance in a timely manner, and on January 20, 2026, Nasdaq advised the Company that it had determined to grant the Company an extension through May 20, 2026 to regain compliance with the Listing Rule.
Nasdaq granted the company an extension until May 20, 2026 to regain compliance after the company submitted a compliance plan. The company completed the debt exchange and equity raise on April 27, 2026, meeting the deadline with minimal time to spare.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · view on EDGAR →
99.1 Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2026.
The company filed an unaudited pro forma condensed consolidated balance sheet as of March 31, 2026. Pro forma financials typically reflect adjustments for significant transactions such as acquisitions, divestitures, or restructurings to show what the financial position would look like under different assumptions. Without the exhibit content, the specific transaction or event driving this pro forma presentation is not disclosed in the 8-K body.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify